Parts of compounds, after being labeled by radionuclide, of the phenyl benzyl ether derivative, are used as A plaque imaging agent. The structural formula of the phenyl benzyl ether derivative is shown by formula (I). The present invention develops a kind of brand new phenyl benzyl ether derivative which has high affinity with A plaques in brains of AD patients. The chemical structure of the phenyl benzyl ether derivative is different from that of compounds disclosed in the prior art and the phenyl benzyl ether derivative belongs to a brand new compound for diagnosing and treating AD. The obtained A plaque imaging agent has the advantages that the in-vivo stability is good, the fat solubility is low, the removal speed for the brain is fast, the problem of removing the radionuclide in vivo does not exist, and the application prospect and the market value are great.

##STR00001##

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection and diagnosis of early stage pancreatic cancer. In preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay can detect a marker for early stage pancreatic cancer in serum. More preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.

The present invention provides compositions and methods for detecting GluA1, as a subunit protein and/or as a GluA1-containing, GluA2-lacking AMPAR complex. The invention further provides composition and methods for detecting and/or diagnosing PTSD. The invention further relates to compositions that can be detected using radiological imaging techniques, and processes for performing such imaging techniques using the compositions, to identify elevated GluA1 expression or activity in a subject, which is a biological marker of PTSD.

Radiopharmaceutical compositions with extended shelf life are provided, including radiopharmaceutical agents that include one or aryl-halide moieties and formulated with a gentisate compound.

The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula (I) or of a salt or a solvate thereof. R.sup.1 is R.sup.1aR.sup.1b wherein R.sup.1a is absent, CH.sub.2, O, or S, and R.sup.1b is CH.sub.2 or CHF. R.sup.2 is (CH.sub.2).sub.3O, (CH.sub.2).sub.3, (CH.sub.2).sub.4, CH.sub.2O(CH.sub.2).sub.2, or CH.sub.2S(CH.sub.2).sub.2. R.sup.3 is ethylene fused to a tricyclic fused ring. L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5b L.sup.5c, L.sup.6 and L.sup.7 are linkages (e.g. peptide bonds). X.sup.br is a branching atom. R.sup.rad is a radiometal chelator. R.sup.alb is an albumin binder. n1, n2, n3, n4, and n5 are integers. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.

##STR00001##

The present invention provides an oligonucleotide conjugate with high hybridization performance and use thereof. The oligonucleotide conjugate of the present invention can be used as a probe for nucleic acid detection, the oligonucleotide conjugate of the present invention can be used to design probes more flexibly, and the conservative regions are more accessible. The specificity of the probe is better, and the fluorescence value of the probe can be significantly improved, the fluorescence background is significantly reduced, and the sensitivity of the probe is greatly improved.

The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally .sup.18F. ##STR00001##

The present invention provides a compound having the structure:

##STR00001##

and methods of using the compound in targeted PET and SPECT imaging.